To date, only PD-L1 expression, microsatellite instability (MSI), and tumor mutational burden (TMB) have been approved by the Food and Drug Administration (FDA) as predictive biomarkers for anti-PD-(L)1 therapies in patients with advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.